[go: up one dir, main page]

AU2003275474A1 - Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors - Google Patents

Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors

Info

Publication number
AU2003275474A1
AU2003275474A1 AU2003275474A AU2003275474A AU2003275474A1 AU 2003275474 A1 AU2003275474 A1 AU 2003275474A1 AU 2003275474 A AU2003275474 A AU 2003275474A AU 2003275474 A AU2003275474 A AU 2003275474A AU 2003275474 A1 AU2003275474 A1 AU 2003275474A1
Authority
AU
Australia
Prior art keywords
inhibitors
beta
growth factor
transforming growth
inhibiting angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003275474A
Other versions
AU2003275474A8 (en
Inventor
Nicholas M. Dean
Eric G. Marcusson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2003275474A1 publication Critical patent/AU2003275474A1/en
Publication of AU2003275474A8 publication Critical patent/AU2003275474A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003275474A 2002-10-07 2003-10-07 Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors Abandoned AU2003275474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41707402P 2002-10-07 2002-10-07
US60/417,074 2002-10-07
PCT/US2003/031778 WO2004032855A2 (en) 2002-10-07 2003-10-07 Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors

Publications (2)

Publication Number Publication Date
AU2003275474A1 true AU2003275474A1 (en) 2004-05-04
AU2003275474A8 AU2003275474A8 (en) 2004-05-04

Family

ID=32093960

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003275474A Abandoned AU2003275474A1 (en) 2002-10-07 2003-10-07 Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors

Country Status (2)

Country Link
AU (1) AU2003275474A1 (en)
WO (1) WO2004032855A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109548A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis

Also Published As

Publication number Publication date
WO2004032855A3 (en) 2005-06-02
WO2004032855A2 (en) 2004-04-22
AU2003275474A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
AU2003247271A1 (en) Method for counteracting the occlusion effects
AU2003268071A1 (en) Method for controlling access to informational objects
PL375974A1 (en) Triazole derivatives as transforming growth factor (tgf) inhibitors
AU2003300286A1 (en) Method and system for supplying high purity fluid
AU2003284399A1 (en) Plk inhibitors
AU2002360993A1 (en) Method for coating objects
AU2003218039A1 (en) Method for reduced methanation
AP2005003263A0 (en) Pyrazole derivatives as transforming growth factor(TGF) inhibitors.
AU2003255333A1 (en) Pyrazole inhibitors of the transforming growth factor
AU2002326949A1 (en) Method for the inhibition of methanogenesis
AU2003271193A1 (en) Method for solid-state single crystal growth
AU2003244412A1 (en) Method for forming electroluminescent devices
AU2002354474A1 (en) Method for supplying solder
AU2003249232A1 (en) Method for managing returns
AU2002950316A0 (en) Plant growth medium
AU2003212748A1 (en) A method for controlling the distribution of data
AU2002320861A1 (en) Method for controlling fermentation
AU2003276284A1 (en) Method for inhibiting yeast growth
AU2003246435A1 (en) Crossflow-filtration method for beverages
AU2003275474A1 (en) Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors
AU2003206984A1 (en) Method for controlling refrigerating installation
AUPS328102A0 (en) Tracking method
AU2003284140A1 (en) Method for inhibiting angiogenesis with ship-1 inhibitors
AU2003242767A1 (en) Method for modifying plants
AU2003253813A1 (en) Method for colpoplasty

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase